Recent Updates
Recently added Catalysts
PCSA

INVESTOR PRESENTATION ex-99.1

Friday, October 20, 2017 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: INVESTOR PRESENTATION ex-99.1

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
1.3%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
VT7208
Phase 1 · Multiple Sclerosis

Full Press Release Details

INVESTOR PRESENTATION ex-99.1.
ShareAdd on Google
Tags: PCSA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 20, 2017

Biotech snapshot

Cash runway
$0M liquidity · $1M/mo burn
~0 mo
High dilution risk
Lead asset
VT7208Phase 1
Multiple Sclerosis →

Catalyst track record

+27%
best trade around PCSA's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for PCSA.

See every catalyst's timing & PoA →